Jiangsu Purecell Biomedical

Jiangsu Purecell Biomedical is a clinical-stage biotechnology company based in Taizhou, China, specializing in the development of innovative immune cell therapies for cancer. The company leverages its proprietary Pure-CAR and Pure-TCR platforms to engineer next-generation chimeric antigen receptor T-cell (CAR-T) and T-cell receptor (TCR-T) treatments. A primary focus of the company is the advancement of universal CAR-T (UCAR-T) technologies, which aim to provide off-the-shelf, cost-effective solutions for patients with hematological malignancies and solid tumors. Operating within the China Medical City, Purecell maintains GMP-compliant manufacturing facilities to support its growing pipeline of therapeutic candidates. The company is dedicated to improving the safety, efficacy, and accessibility of cell-based immunotherapy on a global scale.